TCR2 Therapeutics has been granted a patent for T-cell receptor fusion proteins (TFPs) that target tumor cell antigens. The patent covers engineered T cells expressing TFPs for disease treatment, including cancer. The recombinant nucleic acid includes specific sequences encoding the TFP structure and antigen binding domains. GlobalData’s report on TCR2 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights TCR2 Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on TCR2 Therapeutics, CAR-T cell based therapies was a key innovation area identified from patents.

Recombinant nucleic acid encoding tcr fusion protein for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: TCR2 Therapeutics Inc

A recently granted patent (Publication Number: US11851491B2) discloses a recombinant nucleic acid that encodes a T-cell receptor (TCR) fusion protein (TFP). The TFP includes a TCR subunit with specific domains and antigen binding domains that bind to different antigens. The TFP forms a multimeric TCR complex when expressed on a T cell surface, along with endogenous TCR and CD3 chains. The patent also covers variations where different antigen binding domains are used, such as anti-CD19, anti-CD22, or anti-CD20, and different TCR chains like CD3 epsilon or CD3 gamma.

Furthermore, the patent includes a pharmaceutical composition comprising a human T cell with the recombinant nucleic acid and a pharmaceutically acceptable excipient. Another aspect of the patent involves a recombinant nucleic acid encoding two TFPs linked by a cleavage site, each forming a multimeric TCR complex on T cell surfaces. Variations in antigen binding domains, TCR chains, and sdAb domains like VH are also covered. The patent highlights the potential for these technologies in therapeutic applications involving T cell engineering and immunotherapy, offering a novel approach to modulating immune responses for various medical conditions.

To know more about GlobalData’s detailed insights on TCR2 Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies